Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis

Claudia Marchetti, F. De Felice, I. Palaia, D. Musio, L. Muzii, V. Tombolini, P. Benedetti Panici

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

This meta-analysis was planned to define the role of erythropoiesis-stimulating agents (ESAs) in gynecological cancer patients, receiving myelosuppressive treatment.Pubmed, Medline and Scopus were searched to select English-language articles. Only randomized controlled trials (RCTs) were included. Endpoints were incidence of transfusions, thrombotic events (TE), deaths, and failures. Odd ratio (OR) with 95% confidence interval (CI) was calculated using fixed or random effects model.In seven RCTs ESAs studies of 892 patients under treatment, use of ESAs correlates with a significant reduction of transfusions rate (OR = 0.35; 95% CI: 0.19-0.65; p = 0.008). OR for overall mortality was 1.10 (95% CI 0.82-1.49; p = 0.53). ESAs OR for disease failure in 5 studies was 1.71 (95% CI: 0.90-3.24; p = 0.1).This meta-analysis, even if limited by few RCTs, suggests that ESAs reduce transfusions without increasing mortality or disease progression in gynecological cancer patients receiving treatment.
Lingua originaleEnglish
pagine (da-a)123-128
Numero di pagine6
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume99
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Anemia
  • Chemotherapy
  • Erythropoiesis-stimulating agents
  • Gynecological cancer
  • Mortality
  • Transfusion

Fingerprint

Entra nei temi di ricerca di 'Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis'. Insieme formano una fingerprint unica.

Cita questo